UCEPHAN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Ucephan, and when can generic versions of Ucephan launch?

Ucephan is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in UCEPHAN is sodium benzoate; sodium phenylacetate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the sodium benzoate; sodium phenylacetate profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for UCEPHAN?
What are the global sales for UCEPHAN?
What is Average Wholesale Price for UCEPHAN?

Summary for UCEPHAN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for UCEPHAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	UCEPHAN	sodium benzoate; sodium phenylacetate	SOLUTION;ORAL	019530-001	Dec 23, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for UCEPHAN

See the table below for patents covering UCEPHAN around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Canada	1175750	METHODE POUR ELIMINER LES DECHETS AZOTES (PROCESS FOR WASTE NITROGEN REMOVAL)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for UCEPHAN

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2666774	CA 2020 00037	Denmark	⤷ Start Trial	PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
0290047	SPC/GB97/078	United Kingdom	⤷ Start Trial	PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
1856135	LUC00153	Luxembourg	⤷ Start Trial	PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
2822954	1890030-8	Sweden	⤷ Start Trial	PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
2932970	SPC/GB18/041	United Kingdom	⤷ Start Trial	PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
2673237	201940014	Slovenia	⤷ Start Trial	PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Deep Research

Questions you can ask:

Summary for UCEPHAN

Make Better Decisions: Try a trial or see plans & pricing